Abzena has noted that Gilead Sciences has announced that it is stopping its phase II/III clinical study of GS-5745 in patients with ulcerative colitis.
Abzena says the study termination only affects one indication out of five and Gilead has confirmed that its Phase II and III studies of GS-5745 in patients with gastric cancer, Crohn's disease, rheumatoid arthritis and cystic fibrosis will continue as planned.
Gilead's decision follows a planned interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee which recommended that the study be terminated early due to meeting the pre-specified futility and efficacy criteria. No safety concerns were noted in this interim analysis.
At 9:42am: (LON:ABZA) Abzena Plc share price was -3p at 42p